327 related articles for article (PubMed ID: 21918170)
21. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
Tóth G; Szöőr Á; Simon L; Yarden Y; Szöllősi J; Vereb G
MAbs; 2016 Oct; 8(7):1361-1370. PubMed ID: 27380003
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
23. NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.
Richards JO; Albers AJ; Smith TS; Tjoe JA
Cancer Immunol Immunother; 2016 Nov; 65(11):1325-1335. PubMed ID: 27573917
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
Collins DM; O'Donovan N; McGowan PM; O'Sullivan F; Duffy MJ; Crown J
Ann Oncol; 2012 Jul; 23(7):1788-95. PubMed ID: 22056974
[TBL] [Abstract][Full Text] [Related]
25. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
26. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Beano A; Signorino E; Evangelista A; Brusa D; Mistrangelo M; Polimeni MA; Spadi R; Donadio M; Ciuffreda L; Matera L
J Transl Med; 2008 May; 6():25. PubMed ID: 18485193
[TBL] [Abstract][Full Text] [Related]
27. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
28. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer.
Muraro E; De Zorzi M; Miolo G; Lombardi D; Scalone S; Spazzapan S; Massarut S; Perin T; Dolcetti R; Steffan A; De Re V
Front Immunol; 2021; 12():791958. PubMed ID: 35095867
[TBL] [Abstract][Full Text] [Related]
29. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
Kohrt HE; Houot R; Weiskopf K; Goldstein MJ; Scheeren F; Czerwinski D; Colevas AD; Weng WK; Clarke MF; Carlson RW; Stockdale FE; Mollick JA; Chen L; Levy R
J Clin Invest; 2012 Mar; 122(3):1066-75. PubMed ID: 22326955
[TBL] [Abstract][Full Text] [Related]
30. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
31. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
[TBL] [Abstract][Full Text] [Related]
32. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
34. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
36. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
37. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
38. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.
Kariya Y; Inoue N; Kihara T; Okamoto N; Sugie K; Mori T; Uchida A
Immunol Lett; 1992 Feb; 31(3):241-5. PubMed ID: 1372283
[TBL] [Abstract][Full Text] [Related]
39. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
40. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
